RT @BCD_AACR: Getting ready for today's #17ICML session on #epigenetics of #lymphoma and targeted therapies? Read up on work from BCD Scien…

Getting ready for today's #17ICML session on #epigenetics of #lymphoma and targeted therapies? Read up on work from BCD Scientific Editor Louis Staudt and colleagues identifying and overcoming epigenetic resistance to BTK inhibitors in ABC-DLBCL— https://t

RT @BCD_AACR: If you're attending the #AACR23 session on Evolution of Drug Resistance, read up on work published in Blood Cancer Discovery…

If you're attending the #AACR23 session on Evolution of Drug Resistance, read up on work published in Blood Cancer Discovery on epigenetic resistance to BTK inhibitors in #DLBCL— https://t.co/T7j3muXREL https://t.co/JZ67pIWwSz

RT @BCD_AACR: Learn about the challenges to overcoming drug resistance at #AACR22 session ED018 and read the recent work from @NCIResearchC…

RT @BCD_AACR: Learn about the challenges to overcoming drug resistance at #AACR22 session ED018 and read the recent work from @NCIResearchC…

RT @BCD_AACR: Learn about the challenges to overcoming drug resistance at #AACR22 session ED018 and read the recent work from @NCIResearchC…

Learn about the challenges to overcoming drug resistance at #AACR22 session ED018 and read the recent work from @NCIResearchCtr on epigenetic resistance to BTKi in #DLBCL: https://t.co/aNYiHliif3 https://t.co/j43M1OL6rU

RT @BCD_AACR: Learn about the challenges to overcoming drug resistance at #AACR22 session ED018 and read the recent work from @NCIResearchC…

Learn about the challenges to overcoming drug resistance at #AACR22 session ED018 and read the recent work from @NCIResearchCtr on epigenetic resistance to BTKi in #DLBCL: https://t.co/p3FuRa0fJ1 https://t.co/8lrlei7YAZ

RT @BCD_AACR: #ICYMI: Overcoming Acquired Epigenetic Resistance to BTK Inhibitors by Louis M. Staudt, Arthur L. Shaffer III and colleagues.…

In a population of cells hammered with therapeutics, resistance emerges like a mole from a hole. How does it happen so fast? This study unearthed an epigenetic mechanism:

#ICYMI: Overcoming Acquired Epigenetic Resistance to BTK Inhibitors by Louis M. Staudt, Arthur L. Shaffer III and colleagues. https://t.co/1l3zRvMzvp https://t.co/aObqvsrohP

RT @Lymphoma_Papers: Overcoming Acquired Epigenetic Resistance to BTK Inhibitors #lymphoma #lymsm https://t.co/fVUGYoG1Zl

Overcoming Acquired Epigenetic Resistance to BTK Inhibitors #lymphoma #lymsm https://t.co/fVUGYoG1Zl

New article: Overcoming Acquired Epigenetic Resistance to BTK Inhibitors https://t.co/foapcFjBaJ #CLL #leusm #hematology

New article: Overcoming Acquired Epigenetic Resistance to BTK Inhibitors https://t.co/iMklRxXqqU #DLBCL #lymsm #hematology https://t.co/uYec8oImZ3

#ICYMI: The latest #OnlineFirst focuses on Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. https://t.co/CEM7L5nI2S @theNCI @nih_nhlbi #DLBCL #lymsm #epigenetics #Ibrutinib https://t.co/ZujJJs6S8t

The latest #OnlineFirst: Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. https://t.co/gXCqt00elk @theNCI @nih_nhlbi #DLBCL #lymsm #epigenetics #Ibrutinib https://t.co/KNoikO8nuc

RT @BCD_AACR: We're excited to hear BCD Scientific Editor and #AACRdlbcl21 chair, Louis Staudt, discuss tumor heterogeneity. Read his recen…

RT @BCD_AACR: We're excited to hear BCD Scientific Editor and #AACRdlbcl21 chair, Louis Staudt, discuss tumor heterogeneity. Read his recen…

We're excited to hear BCD Scientific Editor and #AACRdlbcl21 chair, Louis Staudt, discuss tumor heterogeneity. Read his recent paper on investigating and overcoming BTK-inhibitor resistance: https://t.co/wxmsDbZPjF. @theNCI #lymphoma #lymsm https://t.co/1

Resistance to BTK inhibitors in diffuse large B cell lymphoma is driven by epigenetic rather than genetic factors, where RAC2 substitutes for BTK in activation of PLCg2, thereby sustaining NF-kB activity. Important study from Louis Staudt in @BCD_AACR: htt

RT @GreenLymphoLab: Overcoming acquired epigenetic resistance to BTK inhibition. https://t.co/bVOyUHtxh6

RT @GreenLymphoLab: Overcoming acquired epigenetic resistance to BTK inhibition. https://t.co/bVOyUHtxh6

RT @GreenLymphoLab: Overcoming acquired epigenetic resistance to BTK inhibition. https://t.co/bVOyUHtxh6

Overcoming acquired epigenetic resistance to BTK inhibition. https://t.co/bVOyUHtxh6